|
|
Post by mango on Apr 20, 2021 11:57:13 GMT -5
💥 Breaking 4/20 News ✅ Receptor Life Sciences to present 2 presentations at the Respiratory Drug Delivery 2021 conference ⚡️ Kelly Kraft — Using Inhalation To Bypass First-pass Metabolism As A Means Of Improving Cannabidiol Bioavailability ⚡️ Andrea Leone-Bay — An Indirect Pharmacokinetic Comparison Of Cannabidiol Formulations: Dry Power Inhaler (DPI) Vs Vaporization www.rddonline.com/rdd/knowledge_space.php?id=20&sessionID=108 |
|
|
|
Post by mango on Apr 20, 2021 12:02:27 GMT -5
I believe it is April 27.
After April 27, recorded speaker, workshop and poster presentations may be viewed 24/7 as often as you please until June 30, 2021. During this extended conference window, exhibits will also be available and RDD messaging and meeting scheduling will allow you to reach other conference participants.
|
|
|
|
Post by avi8torslc on Apr 20, 2021 14:41:06 GMT -5
Is the a 420 joke? 😆
|
|
|
|
Post by bthomas55ep on Apr 21, 2021 13:40:08 GMT -5
I believe it is April 27. After April 27, recorded speaker, workshop and poster presentations may be viewed 24/7 as often as you please until June 30, 2021. During this extended conference window, exhibits will also be available and RDD messaging and meeting scheduling will allow you to reach other conference participants. |
|
|
|
Post by mango on Apr 28, 2021 8:10:23 GMT -5
ENORMOUS news coming out of our Cannabis partner Receptor Life Sciences today, folks. Cannabidiol Technosphere will absolutely revolutionize the cannabinoid pharmaceutical space. From Andrea Leone-Bay’s accepted poster at Respiratory Drug Delivery 2021 ✅ RLS103 delivered CBD with an efficiency 7-fold greater than a vaporizer ✅ This pharmacokinetic study demonstrated that RLS103 facilitates immediate CBD delivery to the bloodstream with peak concentrations at 3.8 minutes that are 71-fold greater than oral CBD on a dose-adjusted basis ✅ The overall systemic exposure, adjusted for dose, was 9-fold greater than that following oral administration because inhalation delivery bypasses hepatic first-pass metabolism www.receptorlife.com |
|
|
|
Post by akemp3000 on Apr 28, 2021 9:07:35 GMT -5
WOW. We all knew Andrea Leone-Bay is one smart woman who was hired by Al Mann. I believe hearing there are over 100 patents in her name. It was a little puzzling at first why she would leave Al Mann and Mannkind to join RLS since it was a start-up that was not divulging anything. We suspected she knew something big was in the works and happening in her lab behind the scenes. Now we know. In addition to other TS uses, she now holds the key to unlock the first ultra-rapid relief from migraines that not-coincidentally was an issue with Al Mann's wife. Al Mann would be proud. Thanks Mango.
|
|
|
|
Post by sayhey24 on Apr 28, 2021 10:02:50 GMT -5
Hope springs eternal for RLS. Its been a long road. Maybe one day MNKD's pps will be more like GWPH's $200+.
I have never fully understood the relationship between MNKD and RLS and how tight these efforts are. Andrea seemed to be working for MNKD and RLS at the same time, in the beginning. RLS was also doing CBD extraction in Danbury in the beginning before being moved to CA.
Its been a mystery but it looks like it may becoming reality.
|
|
|
|
Post by sellhighdrinklow on Apr 28, 2021 10:09:16 GMT -5
Hope springs eternal for RLS. Its been a long road. Maybe one day MNKD's pps will be more like GWPH's $200+. I have never fully understood the relationship between MNKD and RLS and how tight these efforts are. Andrea seemed to be working for MNKD and RLS at the same time, in the beginning. RLS was also doing CBD extraction in Danbury in the beginning before being moved to CA. Its been a mystery but it looks like it may becoming reality. MNKD royalties (or however classified) are capped at $100 million from RLS. Far from being in perpetuity. Not complaining, just saying ... |
|
|
|
Post by dh4mizzou on Apr 28, 2021 10:17:26 GMT -5
I would presume that could be renegotiated.
|
|
|
|
Post by neil36 on Apr 28, 2021 10:18:36 GMT -5
From the January 2016 Mannkind press release:
Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product.
|
|
|
|
Post by itellthefuture777 on Apr 28, 2021 10:20:34 GMT -5
|
|
|
|
Post by mango on Apr 28, 2021 13:02:30 GMT -5
I am particularly enjoying the disclosure today by RLS that they intend on pursuing not just Acute Panic Attack but also Performance Anxiety in Social Anxiety Disorder with our Cannabidiol Technosphere
✅ RLS103 is being developed for the treatment of acute panic attack in panic disorder and performance anxiety in social anxiety disorder (SAD)
✅ RLS103 delivered CBD with an efficiency 7-fold greater than a vaporizer
✅ This pharmacokinetic study demonstrated that RLS103 facilitates immediate CBD delivery to the bloodstream with peak concentrations at 3.8 minutes that are 71-fold greater than oral CBD on a dose-adjusted basis
✅ The overall systemic exposure, adjusted for dose, was 9-fold greater than that following oral administration because inhalation delivery bypasses hepatic first-pass metabolism
——————————————
I imagine we are turning some heads with information like this.
|
|
|
|
Post by boca1girl on Apr 28, 2021 13:07:24 GMT -5
WOW. We all knew Andrea Leone-Bay is one smart woman who was hired by Al Mann. I believe hearing there are over 100 patents in her name. It was a little puzzling at first why she would leave Al Mann and Mannkind to join RLS since it was a start-up that was not divulging anything. We suspected she knew something big was in the works and happening in her lab behind the scenes. Now we know. In addition to other TS uses, she now holds the key to unlock the first ultra-rapid relief from migraines that not-coincidentally was an issue with Al Mann's wife. Al Mann would be proud. Thanks Mango. Akemp, where did you see the reference to migraines? I don’t see it in the pipeline or the press release. |
|
|
|
Post by akemp3000 on Apr 29, 2021 7:14:36 GMT -5
WOW. We all knew Andrea Leone-Bay is one smart woman who was hired by Al Mann. I believe hearing there are over 100 patents in her name. It was a little puzzling at first why she would leave Al Mann and Mannkind to join RLS since it was a start-up that was not divulging anything. We suspected she knew something big was in the works and happening in her lab behind the scenes. Now we know. In addition to other TS uses, she now holds the key to unlock the first ultra-rapid relief from migraines that not-coincidentally was an issue with Al Mann's wife. Al Mann would be proud. Thanks Mango. Akemp, where did you see the reference to migraines? I don’t see it in the pipeline or the press release. I've seen it mentioned many times but it would take too long to go back and locate the various sources. It does appear her work on migraine relief will be preceded by the other two drugs in the RLS pipeline. I appreciate pointing this out. Al Mann was such a visionary with a laser focus on the biggest unmet medical needs such as diabetes, loss of eyesight, paralysis and more that I remain convinced migraine relief was the catalyst for their relationship that has led to this point and remains a priority for ALB. |
|
|
|
Post by neil36 on Apr 29, 2021 7:43:21 GMT -5
|
|
